
A global shortage means some people with diabetes are struggling to access the drug semaglutide, which is sold under the brand name Ozempic.
The UK’s Department of Health and Social Care has recommended that no new patients are started on the drug. Ongoing shortages have also been reported in Australia and Ireland. Canada has also experienced intermittent shortages.